ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Incidence, mortality and survival of testicular germ cell cancer in the province of Tarragona (Spain), 1980-2018.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTesticular germ cell cancer (TGCC) is a rare malignancy whose incidence is increasing in many European countries. This study aimed to describe the trends in the incidence, mortality, and survival of TGCC and its morphological types (seminoma and non-seminoma) in the province of Tarragona (Spain) over the last four decades, using population-based data from the Tarragona Cancer Registry.
methodsThe study included all incident cases of TGCC diagnosed between 1980 and 2018 in the province of Tarragona. Descriptive and bivariate analyses were performed to examine the association between disease stage and the following variables: period of diagnosis, age, morphology, lactate dehydrogenase (LDH), beta-human chorionic gonadotropin (β-hCG), and alpha-fetoprotein (AFP). Incidence and mortality were assessed by calculating the mean annual number of cases, crude and age-adjusted rates, and the annual percentage change (APC) over the study period. Five- and 10 year survival rates were estimated for all tumors as a whole and stratified by stage, period of diagnosis, age, and morphology.
resultsA total of 458 cases of TGCC were identified, 55% of which were seminomas. The incidence increased significantly over time (APC = 4.3%; 95% CI 3.3-5.3), with the greatest increase observed in men aged 40-49 years. Most cancers were diagnosed at stage I. Mortality remained stable. Survival rates have improved, although not significantly, with 10 year net survival rates exceeding 90% in recent years.
conclusionsThe incidence rates of TGCC have increased in Tarragona, in line with European trends, while survival rates have increased non-significantly, especially in the last decade, probably reflecting advances in treatment and early diagnosis.
Indexed as
Identifiers
42663935What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.